Should Competitors of Negotiated Drugs Review Their Market Strategies?
Manufacturers of therapeutic alternatives to negotiation-eligible drugs should re-examine their commercialization strategies in response to market dynamics.
Featured Video
Hear Our Perspective
We partner closely with clients to ensure their IRA strategy is tailored to their industry position, needs, and goals, helping clients make informed decisions and achieve long-term success.
Video
Planning for Life Sciences
The Inflation Reduction Act brings some of the biggest changes affecting the pharmaceutical industry in the last decade. Megan West discusses how these shifts will impact pharmaceutical organizations and how Avalere can help develop strategies to mitigate risk and identify opportunities throughout the product lifecycle.
Engage an Avalere Expert Today
Featured Expertise
Related Content
Federal and State Policy
IRA Question of the Week: How Will the IRA Impact Product Launch Prices?
Federal and State Policy
IRA Impacts on Patient Access
Federal and State Policy
IRA Question of the Week: How Will the Law Impact Plans and PBMs?
Should Competitors of Negotiated Drugs Review Their Evidence Strategy?
Manufacturers of therapeutic alternatives to negotiation-eligible drugs should examine their value and evidence strategy in response to new dynamics.
Will the IRA Change Investment in Orphan Drug Pipelines?
IRA negotiation eligibility criteria may impact orphan drug investment, affecting long-term innovation and patient access.
Insights on IRA Policies and Business Impacts Presented at Asembia
Avalere’s expert presentations at the AXS23 Summit described IRA drug-pricing policies and the law’s impact on patient access and affordability.
Do Drug Manufacturers Have the Evidence Needed for Price Negotiation?
Manufacturers may find significant gaps between their existing evidence and the negotiation data elements that CMS will evaluate during the negotiation process.
Operational Complexities of Providing Access to MFP for Part D Drugs
Stakeholders in the drug supply chain should consider operational complexities that will result from variable arrangements for accessing the MFP.
Demystifying IRA Drug Price Negotiation
Avalere experts will explore the potential implications of the Inflation Reduction Act (IRA)’s Medicare drug price negotiation program guidance and discuss implementation strategies for the near- and long-term.
IRA Impacts on Evidence and Strategy
Ahead of the Asembia and ISPOR 2023 conferences, Avalere experts discuss the increasing importance of value and evidence strategies as part of Inflation Reduction Act (IRA) implementation planning.
50-State Comparison of Medicaid Adult Vaccine Provider Reimbursement
A new Avalere analysis identified variability in Medicaid physician office, pharmacy, and Federally Qualified Health Centers vaccine reimbursement policies.
How Will the IRA Impact Product Launch Prices?
IRA inflation rebates and drug price negotiation will impact drug launch prices in Medicare, with spillover effects in the Medicaid and commercial markets.
Please wait ...